BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24641480)

  • 1. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of cutaneous T-cell lymphoma.
    Abel EA
    Dermatol Clin; 1985 Oct; 3(4):647-64. PubMed ID: 2878755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycosis fungoides: cutaneous T-cell lymphoma.
    Zaim MT; Grinkemeyer MD
    Am Fam Physician; 1991 May; 43(5):1703-7. PubMed ID: 2021105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group.
    Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL; Michel B; Roenigk HH; Van Scott EJ; Vonderheid EC; Thomas RJ
    Cancer Treat Rep; 1979 Apr; 63(4):701-7. PubMed ID: 376140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
    Graham SJ; Sharpe RW; Steinberg SM; Cotelingam JD; Sausville EA; Foss FM
    Cancer; 1993 Aug; 72(3):726-34. PubMed ID: 8334625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides.
    Tosca A; Linardopoulos S; Malliri A; Hatziolou E; Nicolaidou A; Spandidos DA
    Anticancer Res; 1991; 11(4):1433-8. PubMed ID: 1746900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical staging for cutaneous T-cell lymphoma.
    Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Douglas MC; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL
    Ann Intern Med; 1984 Feb; 100(2):187-92. PubMed ID: 6607008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
    Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
    Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
    Sentis HJ; Willemze R; Scheffer E
    J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
    Dmitrovsky E; Matthews MJ; Bunn PA; Schechter GP; Makuch RW; Winkler CF; Eddy J; Sausville EA; Ihde DC
    J Clin Oncol; 1987 Feb; 5(2):208-15. PubMed ID: 3492594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of progression of early-stage mycosis fungoides, 10-year experience.
    Ariza Gómez SA; Dubeibe Abril PA; Niebles Sincelejo OE; Reina HSL
    An Bras Dermatol; 2024; 99(3):407-413. PubMed ID: 38395632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
    Meissner K; Löning T; Rehpenning W
    Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
    Yamashita T; Abbade LP; Marques ME; Marques SA
    An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
    Sausville EA; Worsham GF; Matthews MJ; Makuch RW; Fischmann AB; Schechter GP; Gazdar AF; Bunn PA
    Hum Pathol; 1985 Nov; 16(11):1098-109. PubMed ID: 3876976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous T cell lymphoma.
    Worobec-Victor SM
    N J Med; 1989 May; 86(5):395-400. PubMed ID: 2662058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
    Safai B
    Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.